WallStSmart
RAPT

RAPT Therapeutics Inc

NASDAQ: RAPT · HEALTHCARE · BIOTECHNOLOGY

$58.02
+0.00% today

Updated 2026-03-04

Market cap
$1.68B
P/E ratio
P/S ratio
411.22x
EPS (TTM)
$-11.66
Dividend yield
52W range
$6 – $58
Volume
3.2M

RAPT Therapeutics Inc (RAPT) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20172018201920202021202220232024
Revenue$0.00$0.00$935000.00$5.04M$3.81M$1.53M$0.00$0.00
Revenue growth (YoY)+439.3%-24.4%-60.0%-100.0%
Cost of revenue$1.38M$1.24M$1.33M$996000.00$2.81M$3.55M$3.54M
Gross profit$-1.38M$-1.24M$-1.33M$5.04M$3.81M$1.53M$-3.55M$-3.54M
Gross margin-142.2%100.0%100.0%100.0%
R&D$25.62M$31.77M$34.91M$45.48M$56.98M$67.08M$101.00M$107.22M
SG&A$3.71M$5.18M$8.72M$12.77M$16.04M$20.24M$26.06M$28.88M
Operating income$-29.33M$-36.95M$-43.63M$-53.21M$-69.21M$-85.80M$-127.06M$-136.10M
Operating margin-4666.2%-1055.4%-1815.1%-5618.5%
EBITDA$-27.95M$-35.71M$-42.30M$-52.09M$-68.21M$-84.75M$-125.85M$-134.90M
EBITDA margin-4524.0%-1033.1%-1789.0%-5550.0%
EBIT$-29.33M$-36.95M$-43.63M$-53.21M$-69.21M$-85.80M$-127.06M$-136.10M
Interest expense$0.00$0.00$2.62M$2.44M$996000.00$1.05M
Income tax$800000.00$660000.00$990000.00$-996000.00$-1.96M
Effective tax rate0.0%-2.3%-1.6%-1.9%1.4%2.3%0.0%0.0%
Net income$-29.11M$-36.15M$-43.00M$-52.89M$-68.21M$-81.88M$-116.80M$-129.87M
Net income growth (YoY)-24.2%-19.0%-23.0%-29.0%-20.0%-42.6%-11.2%
Profit margin-4598.6%-1049.0%-1788.8%-5362.2%

Frequently asked questions

How much free cash flow does RAPT generate?

RAPT produced $-83.42M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is RAPT's balance sheet healthy?

RAPT holds $169.74M in cash and equivalents against — in long-term debt, on $189.90M of shareholder equity. That debt is best read against the cash flow the business throws off each year.